Literature DB >> 28408313

Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management.

T P Johnston1, T A Korolenko2, M Pirro3, A Sahebkar4.   

Abstract

Hypercholesterolemia is one of the major risk factors for the development of cardiovascular disease. Atherosclerosis resulting from hypercholesterolemia causes many serious cardiovascular diseases. Statins are generally accepted as a treatment of choice for lowering low-density lipoprotein (LDL) cholesterol, which reduces coronary heart disease morbidity and mortality. Since statin use can be associated with muscle problems and other adverse symptoms, non-adherence and discontinuation of statin therapy often leads to inadequate control of plasma cholesterol levels and increased cardiovascular risk. Moreover, there is compelling evidence on the presence of still considerable residual cardiovascular risk in statin-treated patients. Ezetimibe improves cholesterol-lowering efficacy and provides mild additional cardiovascular protection when combined with statin treatment. Despite a favorable safety profile compared to statins, ezetimibe-induced cholesterol-lowering is modest when used alone. Hence, there is a critical need to identity additional effective hypolipidemic agents that can be used either in combination with statins, or alone, if statins are not tolerated. Thus, hypolipidemic agents such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, apolipoprotein B-100 antisense oligonucleotides, cholesteryl ester transfer protein (CETP) inhibitors, and microsomal triglyceride transfer protein (MTTP) inhibitors, as well as yeast polysaccharides (beta-glucans and mannans) and compounds derived from natural sources (nutraceuticals) such as glucomannans, plant sterols, berberine, and red yeast rice are being used. In this review, we will discuss hypercholesterolemia, its impact on the development of cardiovascular disease (CVD), and the use of yeast polysaccharides, various nutraceuticals, and several therapeutic agents not derived from 'natural' sources, to treat hypercholesterolemia.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiovascular disease; Hypercholesterolemia; Nutraceuticals

Mesh:

Substances:

Year:  2017        PMID: 28408313     DOI: 10.1016/j.phrs.2017.04.008

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  14 in total

Review 1.  Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors.

Authors:  Rita Del Pinto; Davide Grassi; Giuliana Properzi; Giovambattista Desideri; Claudio Ferri
Journal:  High Blood Press Cardiovasc Prev       Date:  2019-06-24

Review 2.  Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience.

Authors:  Natalie C Ward; Jing Pang; Jacqueline D M Ryan; Gerald F Watts
Journal:  Clin Cardiol       Date:  2018-01-24       Impact factor: 2.882

Review 3.  Cholesterol-Lowering Nutraceuticals Affecting Vascular Function and Cardiovascular Disease Risk.

Authors:  Vanessa Bianconi; Massimo Raffaele Mannarino; Amirhossein Sahebkar; Teresa Cosentino; Matteo Pirro
Journal:  Curr Cardiol Rep       Date:  2018-05-25       Impact factor: 2.931

4.  The Effects of Curcumin on Diabetes Mellitus: A Systematic Review.

Authors:  Ledyane Taynara Marton; Laís Maria Pescinini-E-Salzedas; Maria Eduarda Côrtes Camargo; Sandra M Barbalho; Jesselina F Dos Santos Haber; Renata Vargas Sinatora; Claudia Rucco Penteado Detregiachi; Raul J S Girio; Daniela Vieira Buchaim; Patricia Cincotto Dos Santos Bueno
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-03       Impact factor: 5.555

Review 5.  Update on the Benefits and Mechanisms of Action of the Bioactive Vegetal Alkaloid Berberine on Lipid Metabolism and Homeostasis.

Authors:  Yanwen Wang; Jeffrey A Zidichouski
Journal:  Cholesterol       Date:  2018-07-02

6.  Prevention and Treatment of Atherosclerosis: The Use of Nutraceuticals and Functional Foods.

Authors:  Francesco Visioli; Andrea Poli
Journal:  Handb Exp Pharmacol       Date:  2022

Review 7.  β-glucans and cholesterol (Review).

Authors:  Petr Sima; Luca Vannucci; Vaclav Vetvicka
Journal:  Int J Mol Med       Date:  2018-01-22       Impact factor: 4.101

8.  Egg phospholipids exert an inhibitory effect on intestinal cholesterol absorption in mice.

Authors:  Yoojin Lee; Catherine Y Han; Minkyung Bae; Young-Ki Park; Ji-Young Lee
Journal:  Nutr Res Pract       Date:  2019-06-20       Impact factor: 1.926

9.  Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a.

Authors:  Chuan-Jue Cui; Jing-Lu Jin; Lin-Na Guo; Jing Sun; Na-Qiong Wu; Yuan-Lin Guo; Geng Liu; Qian Dong; Jian-Jun Li
Journal:  J Transl Med       Date:  2020-05-12       Impact factor: 5.531

10.  Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone.

Authors:  Shiva Ganjali; Vanessa Bianconi; Peter E Penson; Matteo Pirro; Maciej Banach; Gerald F Watts; Amirhossein Sahebkar
Journal:  Metabolism       Date:  2020-09-23       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.